Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for February 2012
February 1, 2012
- Dendreon Announces Presentation of PROVENGE Data at the ASCO 2012 Genitourinary Cancers Symposium
- Medivation and Astellas Announce Positive Results From the Phase 3 AFFIRM Trial of MDV3100 in Prostate Cancer Patients Who Received Prior Chemotherapy
- Experimental Neurology Journal: BrainStorm's NurOwn Stem Cell Technology Shows Promise for Treating Huntington's Disease
- Aethlon Medical Reports Immediate and Rapid Virologic Responses in Hepatitis C (HCV) Patients Receiving Hemopurifier Treatment Protocol
- AB Science Reports Positive Clinical Study Data: Masitinib Significantly Extends Overall Survival as compared to Pfizer's Sutent in Gleevec-resistant GIST
- ThermoGenesis Provides Update on Res-Q Clinical Evaluations at Leading Stem Cell Therapy Conference
- NIH Launches Trials To Evaluate CPR And Drugs After Sudden Cardiac Arrest
February 2, 2012
- Phase 1 Study of OGX-427 Presented at the ASCO 2012 Genitourinary Cancers Symposium Shows Early Evidence of Activity in Bladder Cancer
- Clinical Data on OGX-427 Presented at the ASCO 2012 Genitourinary Cancers Symposium Provide Ongoing Evidence of Hsp27 as a Potential Therapeutic Target in Advanced Prostate Cancer
- Clinical Data on OGX-427 Presented at the ASCO 2012 Genitourinary Cancers Symposium Provide Ongoing Evidence of Hsp27 as a Potential Therapeutic Target in Advanced Prostate Cancer
- International Phase I Trial Results of Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) Show All Pharmacokinetic Parameters Significantly Improved in Patients With Severe Hemophilia B
- Cannabis Science Reports Success For 4th Brand New Self-Administering Cancer Patient
- International Phase I Trial Results of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) Show All Pharmacokinetic Parameters Significantly Improved in Patients with Severe Hemophilia B
- Compugen Cancer Target Results Demonstrate Significant Potential for Cancer Immunotherapy
- Lubiprostone Meets Primary Endpoint in Phase 3 Clinical Trial for Opioid-Induced Bowel Dysfunction (OBD)
- Diamyd Medical's Phase III Study Published in The New England Journal of Medicine
February 3, 2012
- Cabozantinib Shows Encouraging Activity in Heavily Pretreated Patients With Advanced Renal Cell Carcinoma
- Acorda Therapeutics Presents Preclinical Data Showing Dalfampridine Improves Motor Function in Chronic Stroke
- Aeterna Zentaris Reports Updated Phase 1 Trial Results for AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer at ASCO GCS Meeting
- Study Published in Neuro-Oncology Journal Shows Brain Tumor Eradication and Prolonged Survival in Mice Treated With Toca 511 and 5-FC
- Young Children Exposed to Anesthesia Multiple Times Show Elevated Rates of ADHD
- High Triglyceride Levels Found to Predict Stroke in Older Women
- Study Finds No Drug-Drug Interaction Between Aggrenox (aspirin/extended-release dipyridamole) 25mg/200mg Capsules and Omeprazole, a Widely Used PPI
February 6, 2012
- Argos Therapeutics Announces New Data Demonstrating Prolonged Overall Survival in a Phase 2 Study of its Arcelis(TM) Immunotherapy AGS-003 in Combination with Sunitinib in Patients with Metastatic Renal Cell Carcinoma (mRCC)
- Novel Drug Shows Significant Promise in Treating Severe Stroke Patients
- Combined Asthma Medication Therapy Shown to Reduce Attacks
- Aeterna Zentaris Reports Updated Phase 1 Trial Results for AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer at ASCO GCS Meeting
- NEJM features two positive pivotal trials of HRA Pharma compound ulipristal acetate for the treatment of uterine fibroids
- Lubiprostone Meets Primary Endpoint in Phase 3 Clinical Trial for Opioid-Induced Bowel Dysfunction (OBD)
February 7, 2012
- Clinical Results from Aduro's Phase 1 Trials Published in Clinical Cancer Research
- Merck Announces Top-Line Results of TRA-2P Study of Vorapaxar
- New Study Evaluates Cialis in parallel with Tamsulosin in Men with Signs and Symptoms Suggestive of Benign Prostatic Hyperplasia
- Anacor Pharmaceuticals Announces Positive Preliminary Results from Two Safety Studies of AN2728 and Updates Atopic Dermatitis Results and Regulatory Status
- Thrasos and Collaborators Publish Nature Medicine Research Article Detailing Potential Treatment Approach for Kidney Disease
- Cannabis Science Awaits Full Biopsy Report As Newest Series of Photos Shows Cancer Lesion Evidently Completely Killed & Hair Re-growth Begins On New Healthy Skin From 2nd Self-Administering Cancer Patient
- Jennerex Publishes Data on JX-594 Cancer Targeting Mechanisms
- Omeros Provides Update on Ongoing OMS302 Phase 3 Clinical Trial
February 8, 2012
- Pivotal Study Published in JAMA Confirms Potential of Novartis Candidate Vaccine Bexsero to Help Protect Infants Against Devastating Meningococcal Serogroup B Disease
- Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase III Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
- Avanir Pharmaceuticals Announces Publication of Phase III Study Results Showing Efficacy and Safety of AVP-923 in the Treatment of Diabetic Neuropathic Pain
- Four-Year Data from Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Sustained or Continued Improvement Across All Endpoints
- Halting Bone-Building Osteoporosis Drug Use Cuts Risk for Additional Atypical Femur Fracture in Half
- Conclusive Results of Regulatory Toxicology Studies With Gft505
February 9, 2012
- ACTT 'Allergy Drops' - Needle Free Allergy Treatment
- Syndax Pharmaceuticals Announces Entinostat Enhanced Activity of Cancer Immunotherapies in Renal and Prostate Cancer Models
- Gene Therapy for Inherited Blindness Succeeds in Patients' Other Eye
- Synageva BioPharma Announces Interim Data at 8th Annual Lysosomal Disease Network (LDN) World Symposium
February 10, 2012
- Soligenix Announces Results From Its Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
- News of Plaque-Clearing Drug Tops Week of Major Advances Against Alzheimer's Disease
February 13, 2012
- New Study Data Published Assessing the Effect of Livalo vs. Crestor on International Normalized Ratio on Steady-State Warfarin
- Foundation Medicine and Dana-Farber Cancer Institute Identify Novel Genomic Alterations in Lung and Colorectal Cancer
- Powerful Three-Drug Combo Shows Promise For People With Rare Blood Disease
February 14, 2012
- PROLOR Biotech Announces Positive Preclinical Results from Comparative Study of its Long-Acting Clotting Factor VIIa
- Injectable Treatment for Blood Clots in Advanced Cancer Patients Increases, According to New Research
- Gene Signal and Collaborators Demonstrate Successful Activity of Topical Aganirsen in Models of Retinal Neovascular disease
- Is lack of VTE protocol adherence putting cancer patients at risk? New study looks at the problem.
- Sirona Biochem Announces Results in Key Study for Biological Inducer
- SuppreMol releases positive interim Phase Ib/IIa results on SM101 in Primary Immune Thrombocytopenia (ITP) trials
- AiCuris Drug Letermovir (AIC246) Meets Primary Efficacy Endpoints in Phase 2 For Human Cytomegalovirus (HCMV) Prophylaxis in Human Blood Precursor Cell Recipients
- Phase 3 Data on HEPLISAV in Adults Aged 18-55 Published in VACCINE
February 15, 2012
- Researchers Show TB4 Provides Both Neuroprotection and Neurorestoration after Traumatic Brain Injury
- Nymox Announces Current Safety Monitoring Committee Results and Update For Phase 3 NX-1207 Trials
- Phosphagenics Delivers Further Positive Oxycodone Patch Trial Results
February 16, 2012
- BiondVax's Universal Flu Vaccine Improves Existing Flu Vaccines in Elderly. In a Second Phase II Trial, the Vaccine Proves Safe and Activates Immunity to Flu
- MicroCHIPS Announces Clinical Results for First Successful Human Trial Of Implantable, Wireless Microchip Drug Delivery Device
- Receptos Scientists Publish Determination of a High Resolution Sphingosine 1-Phosphate Receptor 1 Structure in Science
February 17, 2012
- Gilead Announces Data for Genotype 1 Null Responder Hepatitis C Patients Enrolled in ELECTRON Study
- Innocoll Announces Successful End-of-Phase 2 Meeting with FDA for XaraColl and Agreement of the Phase 3 Program
- New Autism Research Reveals Brain Differences at 6 Months in Infants Who Develop Autism
- New Prostate Cancer Treatment Drugs Could Pack Double Punch
- Is Clot-Busting Drug Safe for Kids with Strokes?
February 21, 2012
- Innocoll Announces Successful End-of-Phase 2 Meeting with FDA for XaraColl® and Agreement of the Phase 3 Program
- BioLineRx Announces Publication of Pre-Clinical Results Demonstrating Efficacy of BL-7010, an Oral Treatment for Celiac Disease and Gluten Sensitivity
- Threshold Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results of TH-302 in Patients With Pancreatic Cancer
- IntelliCell BioScience Inc. Procedure Enables Norwegian Star Basketball Player to Fully Recover from Patella Tendinitis to Play for Manhattan College
- Amsterdam Molecular Therapeutics Receives Request for Further Information From CHMP on Glybera
- Mayo Clinic: Prediabetes May Not Explain Diabetic Polyneuropathies
- Soligenix Announces Positive Survival Results of SGX202 in Radiation Injury
- Repligen Announces FDA Grant of Priority Review for SecreFlo NDA
- Oral Treprostinil New Drug Application Accepted by FDA for Review
February 22, 2012
- Inspiration Biopharmaceuticals Highlights Positive Data on its Recombinant Factor IX for People with Hemophilia B Who Have Undergone Major Surgical Procedures
- FDA Accepts Supplemental Biologics License Application Submitted for ACTEMRA, A Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, Regarding Adult Rheumatoid Arthritis Indication
- Inovio Researchers Successfully Demonstrate RNA Drug Delivery via Electroporation
- Journal Article Reviews Safety and Efficacy Data for IV Ibuprofen, Advocates Expanded Usage
- Takeda Announces Primary Endpoints Met for Pivotal Phase 3 Trial of Vedolizumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Have Failed at Least One Conventional Therapy
- Paladin and Somaxon Announce Filing of New Drug Submission for Silenor
February 23, 2012
- FDA Advisory Committee Recommends Approval of Qnexa
- Gel-Forming Vaginal Tablet Helps To Control Spread Of AIDS
- FDA Accepts Impax Pharmaceuticals NDA Filing for IPX066 for the Treatment of Idiopathic Parkinson's Disease
- PROLOR Biotech to Present Preclinical Data on Its Long-Acting Clotting Factors VIIa and IX at European Hemophilia Conference
- Vertex Announces 12-Week On-Treatment Data and SVR4 From Phase 2 Study of Interferon-Free (All-Oral) Treatment Regimen of INCIVEK, VX-222 and Ribavirin in People with Genotype 1 Hepatitis C
- Pfizer Statement Regarding CDC's ACIP Discussion of Prevnar 13 for Use in Adults
- Genzyme Announces EMA Accepts Oral Teriflunomide Marketing Application for Treatment of Multiple Sclerosis
- Cannabis Science Presents Newest Case Photos of the 3rd Critical Squamous Cell Carcinoma Self-Medicated Cannabis Patient with Clear Continued Improvement
- Obesity Care Continuum (OCC) Applauds FDA Advisory Committee Resounding Approval of QNEXA
February 24, 2012
- Active Biotech and Ipsen Report Tasquinimod (TASQ) Phase II Long Term Safety Data at the 27th European Association of Urology (EAU) Congress
- FDA Advisory Panel Recommends Approval of Chelsea's Northera(droxidopa) for the Treatment of Symptomatic Neurogenic OH
- SNBL USA to Host Developmental Toxicology Session at the 2012 SOT Annual Meeting and ToxExpo in San Francisco, CA
- Forest and Almirall Announce Positive FDA Advisory Committee's Recommendation for Approval of Aclidinium Bromide for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
- Dual Inhibition of MET and VEGF Signaling With Cabozantinib Blocks Tumor Invasiveness and Metastasis
- Millennium Research Institute and UC San Diego Present Data on Pain Treatment at American Academy of Pain Medicine Annual Meeting
- A Different Approach to Lumbar Epidural Steroid Injections Improves the Quality of Life and Everyday Functionality in Patients with Low Back Pain
February 27, 2012
- Phase 2 Data of Takeda?s Investigational GPR40 Agonist, Published in The Lancet, Demonstrated Improved Glycemic Control in Patients with Type 2 Diabetes
- BioSante's Pancreas Cancer Vaccine Shows over 60% Survival Increase in Newly Presented Study
- Watson Receives Complete Response Letter from FDA for Progesterone Vaginal Gel 8%
- Advaxis Low Dose Cohort 1 Meets 50% Efficacy Target In CIN 2/3
- Octapharma USA Submits BLA for octaplasLG, a Therapy Targeting Adverse Transfusion Events
- Nature: BrainStorm's NurOwn Stem Cell Technology Offers Hope for Treating Huntington Disease
- Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting
- Statins Linked with Lower Depression Risk in Heart Disease Patients
- Generex Subsidiary Antigen Express to Present at Prestigious Cancer Immunotherapy Summit
- OncoGenex Announces Data Highlighting OGX-427 at 27th Annual European Association of Urology Congress
- OncoGenex Announces Data Highlighting OGX-427 at 27th Annual European Association of Urology Congress
- Study Links the Risk of Hypogonadism in Men to Long Acting Opioids in Patients Using Daily Opioid Therapy for Chronic Noncancer Pain
February 28, 2012
- Scripps Study Finds Higher Death Risk With Sleeping Pills
- pSivida Corp. Announces Positive Outcome to European Decentralized Procedure for Approval of ILUVIEN for the Treatment of Chronic Diabetic Macular Edema
- Biogen Idec Submits Application to FDA for Approval of Oral BG-12 to Treat Multiple Sclerosis
- Takeda Announes Acceptance of European Marketing Authorization Application for peginesatide, an Investigational Compound for the Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis
- U.S. FDA Grants Priority Review for XARELTO (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
February 29, 2012
- Synta Announces Review of Ganetespib Results in Lung Cancer Presented at IASLC 12th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting
- NW Bio to Present at the Cancer Immunotherapy Summit
- New Publication Describes Allon's davunetide as the Most Advanced Global Drug Candidate for PSP
- Groundbreaking Research Reveals Powerful Protective Immunity Mediated by T cells in Skin and Supports TREM Rx's Approach to Deliver Novel Vaccines to the Skin
- Phase 2b Trial Shows Unique Lipid Efficacy Profile of Novel Compound to Reduce Elevated Triglyceride Levels
- Clinical Development Program receives FDA "Fast Track Designation" and encouraging phase Ib safety results for Viaskin Peanut
- Mitochondrial Dysfunction Present Early in Alzheimer's, Before Memory Loss
- Phase III studies of Jakafi (ruxolitinib) published in The New England Journal of Medicine Demonstrate Significant Clinical Benefit for Patients with Myelofibrosis
- RADARS System Study Indicates Low Rates of Abuse for tapentadol IR
